Update on inborn errors of immunity

Hanna IJspeert; Emily S J Edwards; Robyn E O'Hehir; Virgil A S H Dalm; Menno C van Zelm

doi:10.1016/j.jaci.2024.12.1075

Update on inborn errors of immunity

J Allergy Clin Immunol. 2024 Dec 24:S0091-6749(24)02407-2. doi: 10.1016/j.jaci.2024.12.1075. Online ahead of print.

Authors

Hanna IJspeert¹, Emily S J Edwards², Robyn E O'Hehir², Virgil A S H Dalm³, Menno C van Zelm⁴

Affiliations

¹ Department of Clinical Genetics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
² Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia; Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Australia; Jeffrey Modell Center, Melbourne, Australia.
³ Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; Department of Internal Medicine, Division of Allergy & Clinical Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
⁴ Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia; Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Australia; Jeffrey Modell Center, Melbourne, Australia. Electronic address: [email protected].

PMID: 39724969
DOI: 10.1016/j.jaci.2024.12.1075

Abstract

Ever since the first description of an inherited immunodeficiency in 1952 in a boy with gammaglobulin deficiency, new insights have progressed rapidly in disorders that are now referred to as inborn errors of immunity. In a field where fundamental molecular biology, genetics, immune signaling, and clinical care are tightly intertwined, 2022-24 saw a multitude of advances. Here we report a selection of research updates with a main focus on (1) diagnosis and screening, (2) new genetic defects, (3) susceptibility to severe coronavirus disease 2019 infection and impact of vaccination, and (4) treatment. Importantly, new pathogenic insights more rapidly affect treatment outcomes, either through an earlier and more precise diagnosis or through implementation of novel, personalized treatment. The field is growing rapidly, so awareness, communication, and collaboration are key to improving treatment outcomes.

Keywords: Inborn errors of immunity; JAK inhibitor; PI3K inhibitor; STAT6; V(D)J recombination; diagnosis; gene therapy; hematopoietic stem cell transplantation; newborn screening.

Publication types

Review